Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
April 26, 2018
-
BUSINESS Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
-
BUSINESS Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
-
BUSINESS Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?
April 24, 2018
-
ACADEMIA Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
-
BUSINESS Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
-
BUSINESS Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
-
TRENDS Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
April 20, 2018
-
BUSINESS Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
April 19, 2018
-
ACADEMIA Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
April 19, 2018
-
BUSINESS Another Huge Seller Re-Pricing Won’t Hit Opdivo Unless 195 Billion Yen Sales Reached: Ono Chief
April 18, 2018
-
BUSINESS Sumitomo Dainippon Reorganizes Drug Discovery Research System; Accelerating Decision-Making: Pres.
April 18, 2018
-
REGULATORY Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018
-
BUSINESS Takeda CEO Eager to Lure More Partners to Shonan iPark, Says Diversity Is Source of Creativity
April 16, 2018
-
BUSINESS Shonan Health Innovation Park Marks Grand Opening: Takeda
April 16, 2018
-
ORGANIZATION PhRMA Chief Warns of Serious Implications for Japan Market after 2018 Pricing Reform
April 13, 2018
-
REGULATORY Chuikyo Payer Rep Questions New Premium System for Cost-Based Pricing Method
April 12, 2018
-
REGULATORY MOF Calls for Using CEA to Make Reimbursement Decisions for Pricy Drugs
April 12, 2018
-
REGULATORY Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
April 11, 2018
-
REGULATORY MHLW to Launch New Public-Private Confab Focusing on Drug Pricing
April 10, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…